Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

Company Overview - Curis, Inc. is a biotechnology company focused on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor [3] - Emavusertib is currently in clinical trials, including the Phase 1/2 TakeAim Lymphoma study for relapsed/refractory primary central nervous system lymphoma (PCNSL) and the Phase 1/2 TakeAim Leukemia study for relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (hrMDS) [3] - The drug has received Orphan Drug Designation from the U.S. FDA for treating AML and MDS [3] Upcoming Financial Results - Curis will report its third quarter 2024 financial and operating results on November 14, 2024, at 8:00 a.m. ET [1] - A conference call and webcast will follow at 8:30 a.m. ET on the same day [1][2] Collaboration and Licensing - Curis has an exclusive license to emavusertib through a collaboration with Aurigene established in 2015 [3] - The company has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma [3]